Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Jakafi in MPN and Hodgkin's Lymphoma
NCT04016116Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in Myeloproliferative Neoplasm (MPN), Hodgkin lymphoma (HL), myelofibrosis (MF) and 3 more (3 cohorts), sponsored by NYU Langone Health. Primary endpoint: Progression-Free Survival at 6 months. Planned start Dec 2019; status: withdrawn.
02
Drugs
03
Conditions
Myeloproliferative Neoplasm (MPN)Hodgkin lymphoma (HL)myelofibrosis (MF)polycythemia vera (PV)Myelodysplastic/myeloproliferative neoplasm overlap syndrome (MDS/MPN)
Beyond the preview
Go deeper on NCT04016116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016116.